within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX11_Estramustine;

model Estramustine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.44,
    Cl = 4.1666666666666667e-07,
    adminDuration = 600,
    adminMass = 280 / 1000000,
    adminCount = 1,
    Vd = 0.05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006666666666666667,
    Tlag = 1200);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Estramustine</td></tr><tr><td>ATC code:</td><td>L01XX11</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>280</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>50</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Estramustine is an antineoplastic agent that combines estradiol with a nitrogen mustard, used primarily in the treatment of advanced or metastatic prostate cancer. It acts via both cytostatic and hormonal mechanisms. Estramustine phosphate was historically prescribed in prostate cancer but its clinical use has declined with the introduction of newer agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for male prostate cancer patients following oral administration of estramustine phosphate.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XX11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Estramustine;
